Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)
- 18 June 2020
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 30 (7) , 509-526
Abstract
The peptide hormone glucagon acts as a counterregulatory response to hypoglycemia and as a key driver in the development of all forms of diabetes. Thus, inhibition of glucagon action, including thr...Keywords
This publication has 53 references indexed in Scilit:
- Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II DiabetesJournal of Medicinal Chemistry, 2012
- Physiologic action of glucagon on liver glucose metabolismDiabetes, Obesity and Metabolism, 2011
- Structural insights into agonist-induced activation of G-protein-coupled receptorsCurrent Opinion in Structural Biology, 2011
- A survey of small molecule glucagon receptor antagonists from recent patents (2006 – 2010)Expert Opinion on Therapeutic Patents, 2011
- Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36Gastroenterology, 2009
- Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide ReceptorJournal of Medicinal Chemistry, 2008
- Progress towards glucagon receptor antagonist therapy for Type 2 diabetesExpert Opinion on Therapeutic Patents, 2005
- Approaches to glucagon receptor antagonistsExpert Opinion on Therapeutic Patents, 2003
- Relative quantitative analysis of glucagon receptor mRNA in rat tissuesMolecular and Cellular Endocrinology, 1994
- THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUSThe Lancet, 1975